Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

Abstract Background Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FA...

Full description

Bibliographic Details
Main Authors: Euy Sung Moon, Filipe Elvas, Gwendolyn Vliegen, Stef De Lombaerde, Christel Vangestel, Sven De Bruycker, An Bracke, Elisabeth Eppard, Lukas Greifenstein, Benedikt Klasen, Vasko Kramer, Steven Staelens, Ingrid De Meester, Pieter Van der Veken, Frank Rösch
Format: Article
Language:English
Published: SpringerOpen 2020-07-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
FAP
Online Access:http://link.springer.com/article/10.1186/s41181-020-00102-z
id doaj-6eef6de76ec3424eabc82ef799f24e24
record_format Article
spelling doaj-6eef6de76ec3424eabc82ef799f24e242020-11-25T03:50:04ZengSpringerOpenEJNMMI Radiopharmacy and Chemistry2365-421X2020-07-015112010.1186/s41181-020-00102-zTargeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelatorsEuy Sung Moon0Filipe Elvas1Gwendolyn Vliegen2Stef De Lombaerde3Christel Vangestel4Sven De Bruycker5An Bracke6Elisabeth Eppard7Lukas Greifenstein8Benedikt Klasen9Vasko Kramer10Steven Staelens11Ingrid De Meester12Pieter Van der Veken13Frank Rösch14Department of Chemistry – TRIGA Site, Johannes Gutenberg University MainzDepartment of Nuclear Medicine, Antwerp University Hospital (UZA)Department of Pharmaceutical Sciences, Laboratory of Medical Biochemistry, University of AntwerpDepartment of Nuclear Medicine, Antwerp University Hospital (UZA)Department of Nuclear Medicine, Antwerp University Hospital (UZA)Molecular Imaging Center Antwerp (MICA), University of AntwerpDepartment of Pharmaceutical Sciences, Laboratory of Medical Biochemistry, University of AntwerpPositronpharma SADepartment of Chemistry – TRIGA Site, Johannes Gutenberg University MainzDepartment of Chemistry – TRIGA Site, Johannes Gutenberg University MainzPositronpharma SAMolecular Imaging Center Antwerp (MICA), University of AntwerpDepartment of Pharmaceutical Sciences, Laboratory of Medical Biochemistry, University of AntwerpDepartment of Pharmaceutical Sciences, Laboratory of Medical Biochemistry, University of AntwerpDepartment of Chemistry – TRIGA Site, Johannes Gutenberg University MainzAbstract Background Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed. This inhibitor has been adopted recently by other groups to create radiopharmaceuticals by coupling bifunctional chelator-linker systems. Here, we report squaric acid (SA) containing bifunctional DATA5m and DOTA chelators based on UAMC1110 as pharmacophor. The novel radiopharmaceuticals DOTA.SA.FAPi and DATA5m.SA.FAPi with their non-radioactive derivatives were characterized for in vitro inhibitory efficiency to FAP and PREP, respectively and radiochemical investigated with gallium-68. Further, first proof-of-concept in vivo animal study followed by ex vivo biodistribution were determined with [68Ga]Ga-DOTA.SA.FAPi. Results [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DATA5m.SA.FAPi showed high complexation > 97% radiochemical yields after already 10 min and high stability over a period of 2 h. Affinity to FAP of DOTA.SA.FAPi and DATA5m.SA.FAPi and its natGa and natLu-labeled derivatives were excellent resulting in low nanomolar IC50 values of 0.7–1.4 nM. Additionally, all five compounds showed low affinity for the related protease PREP (high IC50 with 1.7–8.7 μM). First proof-of-principle in vivo PET-imaging animal studies of the [68Ga]Ga-DOTA.SA.FAPi precursor in a HT-29 human colorectal cancer xenograft mouse model indicated promising results with high accumulation in tumor (SUVmean of 0.75) and low background signal. Ex vivo biodistribution showed highest uptake in tumor (5.2%ID/g) at 60 min post injection with overall low uptake in healthy tissues. Conclusion In this work, novel PET radiotracers targeting fibroblast activation protein were synthesized and biochemically investigated. Critical substructures of the novel compounds are a squaramide linker unit derived from the basic motif of squaric acid, DOTA and DATA5m bifunctional chelators and a FAP-targeting moiety. In conclusion, these new FAP-ligands appear promising, both for further research and development as well as for first human application.http://link.springer.com/article/10.1186/s41181-020-00102-zDOTADATA5mGallium-68FAPPREPSquaric acid
collection DOAJ
language English
format Article
sources DOAJ
author Euy Sung Moon
Filipe Elvas
Gwendolyn Vliegen
Stef De Lombaerde
Christel Vangestel
Sven De Bruycker
An Bracke
Elisabeth Eppard
Lukas Greifenstein
Benedikt Klasen
Vasko Kramer
Steven Staelens
Ingrid De Meester
Pieter Van der Veken
Frank Rösch
spellingShingle Euy Sung Moon
Filipe Elvas
Gwendolyn Vliegen
Stef De Lombaerde
Christel Vangestel
Sven De Bruycker
An Bracke
Elisabeth Eppard
Lukas Greifenstein
Benedikt Klasen
Vasko Kramer
Steven Staelens
Ingrid De Meester
Pieter Van der Veken
Frank Rösch
Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators
EJNMMI Radiopharmacy and Chemistry
DOTA
DATA5m
Gallium-68
FAP
PREP
Squaric acid
author_facet Euy Sung Moon
Filipe Elvas
Gwendolyn Vliegen
Stef De Lombaerde
Christel Vangestel
Sven De Bruycker
An Bracke
Elisabeth Eppard
Lukas Greifenstein
Benedikt Klasen
Vasko Kramer
Steven Staelens
Ingrid De Meester
Pieter Van der Veken
Frank Rösch
author_sort Euy Sung Moon
title Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators
title_short Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators
title_full Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators
title_fullStr Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators
title_full_unstemmed Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators
title_sort targeting fibroblast activation protein (fap): next generation pet radiotracers using squaramide coupled bifunctional dota and data5m chelators
publisher SpringerOpen
series EJNMMI Radiopharmacy and Chemistry
issn 2365-421X
publishDate 2020-07-01
description Abstract Background Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed. This inhibitor has been adopted recently by other groups to create radiopharmaceuticals by coupling bifunctional chelator-linker systems. Here, we report squaric acid (SA) containing bifunctional DATA5m and DOTA chelators based on UAMC1110 as pharmacophor. The novel radiopharmaceuticals DOTA.SA.FAPi and DATA5m.SA.FAPi with their non-radioactive derivatives were characterized for in vitro inhibitory efficiency to FAP and PREP, respectively and radiochemical investigated with gallium-68. Further, first proof-of-concept in vivo animal study followed by ex vivo biodistribution were determined with [68Ga]Ga-DOTA.SA.FAPi. Results [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DATA5m.SA.FAPi showed high complexation > 97% radiochemical yields after already 10 min and high stability over a period of 2 h. Affinity to FAP of DOTA.SA.FAPi and DATA5m.SA.FAPi and its natGa and natLu-labeled derivatives were excellent resulting in low nanomolar IC50 values of 0.7–1.4 nM. Additionally, all five compounds showed low affinity for the related protease PREP (high IC50 with 1.7–8.7 μM). First proof-of-principle in vivo PET-imaging animal studies of the [68Ga]Ga-DOTA.SA.FAPi precursor in a HT-29 human colorectal cancer xenograft mouse model indicated promising results with high accumulation in tumor (SUVmean of 0.75) and low background signal. Ex vivo biodistribution showed highest uptake in tumor (5.2%ID/g) at 60 min post injection with overall low uptake in healthy tissues. Conclusion In this work, novel PET radiotracers targeting fibroblast activation protein were synthesized and biochemically investigated. Critical substructures of the novel compounds are a squaramide linker unit derived from the basic motif of squaric acid, DOTA and DATA5m bifunctional chelators and a FAP-targeting moiety. In conclusion, these new FAP-ligands appear promising, both for further research and development as well as for first human application.
topic DOTA
DATA5m
Gallium-68
FAP
PREP
Squaric acid
url http://link.springer.com/article/10.1186/s41181-020-00102-z
work_keys_str_mv AT euysungmoon targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT filipeelvas targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT gwendolynvliegen targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT stefdelombaerde targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT christelvangestel targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT svendebruycker targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT anbracke targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT elisabetheppard targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT lukasgreifenstein targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT benediktklasen targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT vaskokramer targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT stevenstaelens targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT ingriddemeester targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT pietervanderveken targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
AT frankrosch targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators
_version_ 1724492532823359488